H.C. Wainwright starts coverage on Actuate Therapeutics with 'buy' rating

Actuate Therapeutics

17/03/2025 11:43

** Brokerage H.C. Wainwright initiates coverage on biopharma firm Actuate Therapeutics ACTU.O with "buy" rating

** Brokerage sets PT at $20, representing more than 100% upside to the stock's last close

** In a mid-stage study, co's experimental therapy for a type of pancreatic cancer improved overall survival over chemotherapy alone, with a 37% reduction in the risk of death

** Brokerage says the trial data for the therapy, elraglusib, "positions it as a frontrunner among competition" for pancreatic cancer treatments

** Brokerage is optimistic about ACTU because the pancreatic cancer market has a significant unmet need

** Brokerage expects elraglusib to launch in 2029 and believes ACTU has a revenue potential of nearly $600 mln by 2033

** ACTU has fallen 8.9% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))